Laurus Labs Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Additionally, Laurus Labs will co-invest Rs 40 crore at the same valuation. The promoters of Laurus Bio have been issued share warrants, exercisable within two years from the date of issue at the same valuation. Laurus Labs and Eight Roads Ventures have the right to invest up to an additional Rs 35 crore before December 2025 at the same valuation.

Upon completion of the transaction, Laurus Labs, Eight Roads Ventures, and the promoters of Laurus Bio will hold 75%, 14%, and 9% stakes, respectively, on a fully diluted basis. The company will use the equity infusion to expand its fermentation-based manufacturing capabilities to meet growing customer demand.

Satyanarayana Chava, founder & CEO of Laurus Labs, and Rajesh Krishnamurthy, CEO of Laurus Bio, commented, “We are pleased to announce rejoining the partnership with Eight Roads Ventures and Laurus Lab’s continued commitment with an additional investment into Laurus Bio. The company, promoters of Laurus Bio, Eight Roads Ventures, and F-Prime Capital will drive expansion of the manufacturing and R&D infrastructure to further accelerate growth opportunities.

Eight Roads Ventures brings a global network, relevant industry experience, and a strong track record of biopharmaceuticals and CDMO investing. This investment will enable the company to further expand and accelerate microbial-fermentation capabilities, including faster development of new products, speed-up internal pipeline, enhancing high-quality commercial-scale capacity to partners, and growing our industry position.”

Prem Pavoor, Managing Partner, Eight Roads Ventures India, said, “We are thrilled to re-unite with two of our former partners, Laurus Labs & Laurus Bio, who have built a best-in-class biomanufacturing platform to cater to the growing global demand for sustainable manufacturing technologies. Biomanufacturing is already being utilized across a range of industries, including personal care, materials, food and nutrition, and pharmaceuticals. We are looking forward to growing Laurus Bio into a global leader in this emerging segment.”

Laurus Labs is a fully integrated pharmaceutical and biotechnology company with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral, oncology drugs, cardiovascular, gastro, and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations and provides contract research and manufacturing services (CRAMS) to global pharma companies.

The company’s consolidated net profit tumbled 46.35% to Rs 19.84 crore in Q2 FY25 as against Rs 36.95 crore posted in Q2 FY24. Net sales marginally declined to Rs 1,223.70 crore in Q2 FY25 from Rs 1,224.45 crore reported in Q2 FY24.

Shares of JSW Energy rose 0.25% to close at Rs 589.60 on Friday, 6 December 2024.

Powered by Capital Market - Live News

Laurus Labs announced that its subsidiary, Laurus Bio, has signed a definitive agreement for an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital. Laurus Labs also agreed to co-invest an additional Rs 40 crore at the same valuation. The Promoters of Laurus Bio have also been issued share warrants, exercisable up to two years from the date of issue at the same valuation.

Laurus Labs or Eight Roads Ventures have the right to invest up to an additional amount of Rs 35 crore before Dec 2025 at the same valuation. Upon completion of the transaction, the Company, Eight Roads Ventures and the Promoters of Laurus Bio will hold 75%, 14% and 9% stake respectively on a fully diluted basis. The Company will utilize the equity infusion for further expansion of its fermentation-based manufacturing capabilities in order to cater to growing customer demand.

Powered by Capital Market - Live News

Laurus Labs Ltd gained for a fifth straight session today. The stock is quoting at Rs 582.25, up 0.27% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.07% on the day, quoting at 24439.9. The Sensex is at 80883.01, up 0.05%. Laurus Labs Ltd has gained around 19.01% in last one month.

Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has gained around 1.21% in last one month and is currently quoting at 22445.7, down 0.26% on the day. The volume in the stock stood at 14.43 lakh shares today, compared to the daily average of 27.76 lakh shares in last one month.

The benchmark December futures contract for the stock is quoting at Rs 582, down 0.06% on the day. Laurus Labs Ltd is up 54.71% in last one year as compared to a 17.19% jump in NIFTY and a 37.94% jump in the Nifty Pharma index.

The PE of the stock is 133.14 based on TTM earnings ending September 24.

Powered by Capital Market - Live News

Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 577.25, up 1.78% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 24184. The Sensex is at 79872.83, up 0.09%. Laurus Labs Ltd has added around 18.42% in last one month.

Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 0.69% in last one month and is currently quoting at 22240.2, up 1.08% on the day. The volume in the stock stood at 29.18 lakh shares today, compared to the daily average of 27.12 lakh shares in last one month.

The benchmark December futures contract for the stock is quoting at Rs 580.3, up 1.89% on the day. Laurus Labs Ltd is up 52.21% in last one year as compared to a 16.91% gain in NIFTY and a 38.53% gain in the Nifty Pharma index.

The PE of the stock is 129.98 based on TTM earnings ending September 24.

Powered by Capital Market - Live News